Exelixis director sells 3,856 shares in plan trade

Exelixis director Sue Gail Eckhardt reported an open-market sale of 3,856 shares of common stock on February 13, 2026 at a weighted average price of $43.79 per share.

Rhea-AI Filing Summary

Exelixis director Sue Gail Eckhardt reported an open-market sale of 3,856 shares of common stock on February 13, 2026 at a weighted average price of $43.79 per share. The transaction was executed under a prearranged Rule 10b5-1 trading plan adopted on November 11, 2025. After this sale, she beneficially owns 17,524 shares, including shares that will be issued upon vesting of restricted stock units.

Insider Trade Summary

Net Seller: 3,856 shares

Net Sell 1 txn

Insider Eckhardt Sue Gail

Role Director

Sold 3,856 shs ($169K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,856	$43.79	$169K

Holdings After Transaction: Common Stock — 17,524 shares (Direct)

Footnotes (3)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2025.
2. F2. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $42.89 to $43.89. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.
3. F3. Includes 17,524 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Exelixis (EXEL) disclose for Sue Gail Eckhardt?

Exelixis reported that director Sue Gail Eckhardt sold 3,856 shares of common stock. The sale was an open-market transaction executed under a Rule 10b5-1 trading plan and was reported on a Form 4 insider filing.

How many Exelixis (EXEL) shares did the director sell and at what price?

Sue Gail Eckhardt sold 3,856 Exelixis common shares at a weighted average price of $43.79. The shares were sold in multiple trades within a price range from $42.89 to $43.89 per share, according to the filing footnotes.

Was the Exelixis (EXEL) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by Sue Gail Eckhardt on November 11, 2025. Such plans pre-schedule trades, aiming to reduce concerns about trading on nonpublic information.

How many Exelixis (EXEL) shares does the director own after the sale?

After the reported sale, Sue Gail Eckhardt beneficially owns 17,524 shares of Exelixis common stock. This total includes shares that will be issued upon vesting of restricted stock units, each equivalent to one common share.

What price range did the Exelixis (EXEL) insider sales cover?

The filing notes that the 3,856 shares were sold at prices ranging from $42.89 to $43.89 per share. The reported $43.79 figure is a weighted average sales price across multiple individual transactions within that range.

What are the restricted stock units mentioned in the Exelixis (EXEL) Form 4?

The Form 4 explains that the director’s holdings include restricted stock units, or RSUs, that will convert into 17,524 Exelixis common shares upon vesting. Each RSU is economically equivalent to one share of common stock when it vests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 08:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eckhardt Sue Gail

(Last) (First) (Middle)

C/O EXELIXIS, INC.

1851 HARBOR BAY PARKWAY

(Street)

ALAMEDA CA 94502

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXELIXIS, INC. [ EXEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		S(1)		3,856	D	$43.79(2)	17,524(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2025.

2. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $42.89 to $43.89. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

3. Includes 17,524 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock.

Remarks:

	/s/ Nina Ayer, Attorney in Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.